ICYMI: 5 Most Recent FDA Approvals, June 23, 2020
The FDA has had a busy couple of weeks, approving new agents to treat a variety of cancers.
As spring turns to summer, the FDA is not slowing down in approving drugs in the oncology space — some for very specific cancer types, and others (such as the recent approval of pembrolizumab) for a whole range of solid tumors that have a high mutational burden.
In case you missed it, here is a list of the 5 most recent FDA approvals:
- Selinexor for relapsed/refractory diffuse large Bcell lymphoma (DLBCL). The approval is for patients with this subtype of nonHodgkin lymphoma who have had 2 or more prior therapies.
- Tazemetostat for relapsed/refractory follicular lymphoma. This drug was also approved for patients who have had at least 2 prior therapies, or for those with relapsed/refractory follicular lymphoma who have no other satisfactory treatment options available.
- Pembrolizumab for tumor mutational burdenhigh solid tumors. The immunotherapy agent’s approval is for both pediatric and adult patients with solid tumors whose disease has at least 10 mutations/megabase.
- Gemtuzumab ozogamicin for pediatric acute myeloid leukemia. Children aged 1 month or older can now be treated with gemtuzumab ozogamicin if their disease is CD33—positive.
- Lurbinectedin for metastatic small cell lung cancer. The approval is for patients with small cell lung cancer whose disease progressed after a platinumbased chemotherapy.
Sign up for Oncology Nursing News emails and never miss an approval or the latest in the field of oncology nursing.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
